PHAT Phathom Pharmaceuticals, Inc.: institutional ownership and insider trading
169 funds reported holding $853M of Phathom Pharmaceuticals, Inc. in their latest 13F filings; in Q2 2026 funds net bought $33.9M, with 20 new positions and 32 funds selling out; over the last 12 months insiders bought $0 and sold $7.08K on the open market; over its last four quarters it reported revenue of $240M and net income of $122M.
PHAT revenue and earnings
- Quarter ended Jun 30, 2026: revenue $74.3M, net income −$17.6M, EPS -0.21
- Quarter ended Mar 31, 2026: revenue $58.3M, net income −$30.4M, EPS -0.37
- Quarter ended Dec 31, 2025: revenue $57.6M, net income $200M, EPS -0.26
- Quarter ended Sep 30, 2025: revenue $49.5M, net income −$30.0M, EPS -0.41
Famous investors holding PHAT
- Izzy Englander (Millennium Management): $36.6M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $7.56M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $5.63M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $2.46M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $1.04M, 0.0% of the portfolio
Largest institutional holders of PHAT
- Frazier Life Sciences Management, L.P. — $135M
- Medicxi Ventures Management (Jersey) Ltd — $81.0M
- VANGUARD GROUP INC — $52.7M
- BlackRock, Inc. (BLK) — $49.1M
- Invesco Ltd. (IVZ) — $43.7M
- Carlyle Group Inc. (CG, CGABL) — $37.9M
- MILLENNIUM MANAGEMENT LLC — $36.6M
- VANGUARD CAPITAL MANAGEMENT LLC — $28.8M
- GW&K Investment Management, LLC — $23.5M
- WASATCH ADVISORS LP — $21.5M
Recent PHAT insider trades
- Nov 3, 2025: Breedlove Robert Charles sold 524 shares ($7.08K)
- Sep 5, 2025: Breedlove Robert Charles sold 461 shares ($5.57K)
- Jul 16, 2025: Breedlove Robert Charles sold 1,692 shares ($14.1K)
- May 21, 2025: Topper James N bought 3,780 shares ($14.6K)
5%+ owners
- BlackRock, Inc.: 5.5% (Schedule 13G, filed Jul 29, 2026)